



REINSURANCE **HOT NEWS**

July 17 TH, 2026

AHCCCS is pleased to announce the addition 3 of the following drugs to the High-Cost Specialty Drug Reinsurance (BIO) effective:

Effective October 1, 2026:

Kresladi-Indicated for the treatment of severe leukocyte adhesion deficiency-I (LAD-I) in pediatric patients due to biallelic variants in ITGB2 without an available human leukocyte antigen (HLA)-matched sibling donor for allogeneic hematopoietic stem cell transplant

Effective July 1, 2026:

Crysvita- Indicated for:

- The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.
- The treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.

Effective June 1, 2026:

Avlayah- Indicated for the treatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II, MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment.

*Language added to **Korlym** ‘Additional Reinsurance Information’

Reminder from the Reinsurance Manual (Page 20)

"For multiple reinsurance drugs to treat the same medical condition, please refer to the AHCCCS Fee For Service prior authorization criteria to determine if the criterion supports the use of multiple medications given/administered at the same time to an individual. When the prior authorization criterion is not supportive of the use of multiple drugs to treat the same condition, the reinsurance program will not reimburse multiple medications. For additional questions, please check with the Medical Management staff assigned to the MCO. "

Here is the Link to the Updated High-Cost Specialty Drug List:
<https://www.azahcccs.gov/PlansProviders/Downloads/Reinsurance/BiologicandHighCostSpecialtyDrugList.xlsx>

